Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Paragon Care Limited (PGC.AX)
Mount Waverley, VIC, AU
Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohematology laboratories; offers ophthalmology and optometry, neonatal vision screening solutions, and procedural kits. It also provides neonatal and paediatric assessment, including newborn hearing and vision screening, jaundice management, NICU video monitoring, brain monitoring, breast milk tracking, electrodes; sterilisable transducers designed for surgical procedures, digital theatre integration, infection control, infusion therapy, temperature management, enteral feeding, pain management, lasers, operating room products, surgical consumables, and ultrasound systems. In addition, the company offers aesthetic devices for dermatologists, cosmetic surgeons, general practitioners, beauty and aesthetic providers, and educational institutions; natural, traditional, and complementary health products and services; critical care and dental solutions; urology solutions, such as shockwave therapy, lasers, and accessories for infection control; medical products and consumables; and orthopaedics solutions, including hip and knee arthroplasty, upper and lower extremity, sports medicine, reverse shoulder replacement, and powered surgical tools. Further, it offers medical equipment repair, maintenance, and support services; technology and communication solutions, such as telephony, nurse call, access control, cctv, cordless, and Wi-Fi; supplies medical equipment to veterans, war widows, and families; and veterinary products. Additionally, it is involved in maintenance of technical medical equipment to the health, aged care, and veterinary markets; and distribution of pharmaceuticals, medical consumables, and complementary medicines to Australian healthcare market. The company is based in Mount Waverley, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +3.45% | +0.00% | -21.05% | -49.15% | -30.23% | -62.50% | -65.12% | -65.12% | -65.12% | -65.12% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+21.7% ★ Q4'25: +1,094.6% (vs Q4'23)
-
EPS growth Medical - Distribution: +4.9%+37.8% ★ Q4'25: -390.9% (vs Q4'23)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-1.1% Q4'25: -1.9% (vs Q4'23)
-
EBIT margin Medical - Distribution: +3.0%+1.7% Q4'25: -1.0% (vs Q4'23)
-
ROIC Medical - Distribution: +5.7%+8.2% ★ Q4'25: -7.3% (vs Q4'23)
-
Share dilution Medical - Distribution: +0.0%+77.2% Q4'25: +142.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×3.30× Q4'25: -26.28× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 2 Rev. Ana. 2 EPS Ana. |
Jun 2027 2 Rev. Ana. 2 EPS Ana. |
Jun 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
32.22M
est: 30.70M (+5.0%)
|
93.38M
est: 93.05M (+0.4%)
|
117.19M
est: 115.11M (+1.8%)
|
117.20M
est: 141.40M (-17.1%)
|
236.01M
est: 260.05M (-9.2%)
|
231.69M
est: 240.00M (-3.5%)
|
235.84M
est: 232.10M (+1.6%)
|
237.62M
est: 255.25M (-6.9%)
|
307.63M
est: 321.60M (-4.3%)
|
2.97B
est: 2.06B (+43.9%)
|
3.61B
est: 3.74B (-3.4%)
|
3.66B
3.63B – 3.69B
-2.3% YoY
|
3.68B
3.65B – 3.72B
+0.8% YoY
|
3.87B
3.86B – 3.89B
+5.2% YoY
|
| EBITDA |
3.74M
est: 2.29M (+63.2%)
|
12.14M
est: 8.22M (+47.6%)
|
17.16M
est: 12.45M (+37.8%)
|
22.39M
est: 16.84M (+33.0%)
|
28.27M
est: 23.01M (+22.8%)
|
-63.54M
est: -16.43M (-286.8%)
|
26.54M
est: -95.39M (+127.8%)
|
23.96M
est: -97.73M (+124.5%)
|
37.07M
est: -101.95M (+136.4%)
|
43.18M
est: -106.47M (+140.6%)
|
89.81M
est: 279.36M (-67.9%)
|
272.93M
270.66M – 275.21M
-2.3% YoY
|
275.03M
272.52M – 277.54M
+0.8% YoY
|
289.25M
287.94M – 290.55M
+5.2% YoY
|
| EBIT |
3.39M
est: 1.64M (+107.0%)
|
11.37M
est: 8.22M (+38.4%)
|
16.03M
est: 12.45M (+28.7%)
|
20.03M
est: 16.84M (+18.9%)
|
18.15M
est: 36.11M (-49.7%)
|
-71.59M
est: 17.76M (-503.1%)
|
20.34M
est: -74.39M (+127.3%)
|
16.02M
est: -76.22M (+121.0%)
|
26.78M
est: -79.51M (+133.7%)
|
28.71M
est: 109.83M (-73.9%)
|
59.98M
est: 199.81M (-70.0%)
|
195.22M
193.59M – 196.84M
-2.3% YoY
|
196.72M
194.92M – 198.51M
+0.8% YoY
|
206.89M
205.95M – 207.82M
+5.2% YoY
|
| Net Income |
2.10M
est: 64.36M (-96.7%)
|
7.53M
est: 80.23M (-90.6%)
|
10.17M
est: 9.50M (+7.1%)
|
10.95M
est: 12.04M (-9.0%)
|
8.86M
est: 19.75M (-55.1%)
|
-77.27M
est: -13.99M (-452.3%)
|
8.28M
est: -81.95M (+110.1%)
|
6.63M
est: -83.97M (+107.9%)
|
12.80M
est: 12.80M (+0.0%)
|
8.38M
est: 8.38M (+0.0%)
|
20.57M
est: 28.17M (-27.0%)
|
26.53M
26.00M – 27.06M
-5.8% YoY
|
32.33M
32.05M – 32.61M
+21.9% YoY
|
41.45M
36.83M – 46.07M
+28.2% YoY
|
| SGA |
9.17M
est: 5.33M (+72.0%)
|
18.71M
est: 27.97M (-33.1%)
|
22.62M
est: 23.61M (-4.2%)
|
32.14M
est: 26.76M (+20.1%)
|
68.65M
est: 55.93M (+22.7%)
|
58.73M
est: 64.30M (-8.7%)
|
57.96M
est: 77.76M (-25.5%)
|
68.82M
est: 79.67M (-13.6%)
|
81.29M
est: 83.11M (-2.2%)
|
129.57M
est: 357.41M (-63.7%)
|
92.58M
est: 650.25M (-85.8%)
|
635.30M
630.01M – 640.60M
-2.3% YoY
|
640.19M
634.35M – 646.04M
+0.8% YoY
|
673.28M
670.24M – 676.32M
+5.2% YoY
|
| EPS |
0.03
est: 0.04 (-18.9%)
|
0.06
est: 0.05 (+15.3%)
|
0.06
est: 0.06 (+8.1%)
|
0.05
est: 0.06 (-7.1%)
|
0.01
est: 0.03 (-48.5%)
|
-0.12
est: 0.02 (-600.0%)
|
0.02
est: 0.03 (-23.4%)
|
0.01
est: 0.02 (-23.8%)
|
0.02
est: 0.02 (-15.2%)
|
0.01
est: 0.01 (-38.6%)
|
0.01
est: 0.02 (-27.1%)
|
0.02
0.02 – 0.02
-5.9% YoY
|
0.02
0.02 – 0.02
+21.9% YoY
|
0.03
0.02 – 0.03
+28.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 15.9K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Keith Collins | Executive Director of M&A and Director | 1M | male |
| Carmen Rose Riley | MD, Chief Executive Officer & Director | 606.2K | female |
| Brendon Pentland | Chief Financial Officer | 418.0K | male |
| James Khoshaba | Chief Information Officer | — | male |
| Marnie Morton | Chief People Officer | — | female |
| Michael Sapountzis | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PGC.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
